OUTLOOK THERAPEUTICS INC (OTLK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.38 Million) by net assets ($-32.19 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OTLK equity to assets ratio to measure how much of total assets are equity-financed.
OUTLOOK THERAPEUTICS INC - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is OUTLOOK THERAPEUTICS INC's earnings quality to evaluate the quality of earnings relative to operating cash generation.
OUTLOOK THERAPEUTICS INC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Openbase Inc
KQ:049480
|
0.018x |
|
Bumyang Construction Co Ltd
KO:002410
|
1.569x |
|
First Graphene Ltd
F:M11
|
-0.111x |
|
Vate Technology Co Ltd
TWO:5344
|
-0.022x |
|
NBI Bearings Europe S.A.
MC:NBI
|
0.043x |
|
Mundial S.A. - Produtos de Consumo
SA:MNDL3
|
0.240x |
|
Lotte Chilsung Beverage Co Ltd
KO:005305
|
0.033x |
|
Sheh Kai Precision Co Ltd
TWO:2063
|
0.067x |
Annual Cash Flow Conversion Efficiency for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual cash flow conversion efficiency of OUTLOOK THERAPEUTICS INC from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of OUTLOOK THERAPEUTICS INC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $-32.19 Trillion | $-51.83 Trillion | 1.610x | +71.05% |
| 2024-09-30 | $-73.08 Million | $-68.79 Million | 0.941x | -68.37% |
| 2023-09-30 | $-14.44 Million | $-42.97 Million | 2.976x | +145.88% |
| 2022-09-30 | $8.74 Million | $-56.67 Million | -6.487x | +44.91% |
| 2021-09-30 | $4.61 Million | $-54.25 Million | -11.776x | -4.69% |
| 2020-09-30 | $2.83 Million | $-31.79 Million | -11.249x | -475.20% |
| 2019-09-30 | $-10.77 Million | $-32.29 Million | 2.998x | +88.84% |
| 2018-09-30 | $-20.81 Million | $-33.04 Million | 1.588x | +214.62% |
| 2017-09-30 | $-30.73 Million | $-15.51 Million | 0.505x | -94.23% |
| 2016-09-30 | $-5.20 Million | $-45.48 Million | 8.746x | +649.60% |
| 2015-09-30 | $-23.55 Million | $-27.48 Million | 1.167x | +386.24% |
| 2014-09-30 | $-29.26 Million | $-7.02 Million | 0.240x | -- |
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more